Basic Information
Suliqua
Regulatory Information
EMEA/H/C/004243
January 11, 2017
November 10, 2016
14
October 25, 2024
Company Information
France
82 Avenue Raspail 94250 Gentilly
SANOFI WINTHROP INDUSTRIE
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without SGLT-2 inhibitors.
Overview Summary
Suliqua is a medicine that is used together with metformin (another diabetes medicine), with or without SGLT-2 inhibitors (other diabetes medicines), for the treatment of adults with type 2 diabetes. It is used with appropriate diet and exercise to improve control of blood glucose (sugar) when the diabetes is not satisfactorily controlled. The active substances in Suliqua are insulin glargine and lixisenatide.